Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
# START YOAST BLOCK # --------------------------- User-agent: * Disallow: Sitemap: https://www.arvinas.com/sitemap_index.xml # --------------------------- # END YOAST |
Title | Protein Degradation with PROTAC Protein Degraders | |
Description | Latest Arvinas is a clinical-stage biotechnology company leading the way in targeted protein degradation |
Keywords | N/A |
WebSite | arvinas.com |
Host IP | 162.247.143.142 |
Location | United States |
Site | Rank |
US$39,212,015
Last updated: 2023-04-28 12:53:48
arvinas.com has Semrush global rank of 269,925. arvinas.com has an estimated worth of US$ 39,212,015, based on its estimated Ads revenue. arvinas.com receives approximately 4,524,464 unique visitors each day. Its web server is located in United States, with IP address 162.247.143.142. According to SiteAdvisor, arvinas.com is safe to visit. |
Purchase/Sale Value | US$39,212,015 |
Daily Ads Revenue | US$36,196 |
Monthly Ads Revenue | US$1,085,872 |
Yearly Ads Revenue | US$13,030,455 |
Daily Unique Visitors | 301,631 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
arvinas.com. | A | 598 | IP: 162.247.143.142 |
arvinas.com. | NS | 3600 | NS Record: ns21.domaincontrol.com. |
arvinas.com. | NS | 3600 | NS Record: ns22.domaincontrol.com. |
arvinas.com. | MX | 3600 | MX Record: 0 arvinas-com.mail.protection.outlook.com. |
arvinas.com. | TXT | 3600 | TXT Record: v=spf1 mx include:spf.protection.outlook.com include:_spf.createsend.com include:contegix.com include:spfa.contegix.com include:spfb.contegix.com ip4:72.237.76.112 ~all |
Search Close this search box. Search Close this search box. Propelling the Future With Targeted Protein Degradation Our Mission is to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC® protein degradation platform. We are Arvinas, a clinical-stage biotechnology company leading the way in the development of targeted protein degradation therapeutics. We are singularly focused on developing an entirely new class of medicines that aims to be transformative for patients and their health care providers, turning targeted protein degradation into one of the most promising areas of medical research and challenging the perceived limits of drug discovery. Learn more about our platform Latest News Arvinas to Present at Stifel Targeted Oncology Day April 21, 2023 Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership April 3, 2023 Arvinas Reports Fourth Quarter and Full Year 2022 |
HTTP/1.1 200 OK Server: nginx Date: Thu, 21 Oct 2021 13:27:36 GMT Content-Type: text/html; charset=UTF-8 Connection: keep-alive Vary: Accept-Encoding Permissions-Policy: interest-cohort=() |
Domain Name: ARVINAS.COM Registry Domain ID: 1748797355_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2015-10-06T18:00:36Z Creation Date: 2012-09-30T02:12:55Z Registry Expiry Date: 2025-09-30T02:12:55Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS21.DOMAINCONTROL.COM Name Server: NS22.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-10T07:17:57Z <<< |